U.S. regulators on Friday granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca PLC.
Dec 19, 2014
4.5 / 5 (2) | 0
(HealthDay)—The number of invasive diagnostic procedures, including amniocentesis, is down significantly after the introduction of noninvasive prenatal testing (NIPT), according to a study published in ...
Dec 18, 2014
not rated yet | 0